BG103143A - Заместени пиридо- или пиримидосъдържащи 6,6- или 6,7- бициклични производни - Google Patents

Заместени пиридо- или пиримидосъдържащи 6,6- или 6,7- бициклични производни

Info

Publication number
BG103143A
BG103143A BG103143A BG10314399A BG103143A BG 103143 A BG103143 A BG 103143A BG 103143 A BG103143 A BG 103143A BG 10314399 A BG10314399 A BG 10314399A BG 103143 A BG103143 A BG 103143A
Authority
BG
Bulgaria
Prior art keywords
pirimidocontaining
substituted pyrido
bicyclic derivatives
bicyclic
derivatives
Prior art date
Application number
BG103143A
Other languages
English (en)
Inventor
Yuhpyng Chen
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of BG103143A publication Critical patent/BG103143A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Изобретението се отнася до съединения с формула, в която А, В, D, E, K, G, Z, R3 и R5 имат значенията, посочени в описанието, и до фармацевтично приемливите им соли. Те саантагонисти на освобождаващ кортикотропин фактор (хормон) CRF (CRH).
BG103143A 1996-08-06 1999-02-03 Заместени пиридо- или пиримидосъдържащи 6,6- или 6,7- бициклични производни BG103143A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2345396P 1996-08-06 1996-08-06
PCT/IB1997/000918 WO1998005661A1 (en) 1996-08-06 1997-07-23 Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives

Publications (1)

Publication Number Publication Date
BG103143A true BG103143A (bg) 1999-09-30

Family

ID=21815208

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103143A BG103143A (bg) 1996-08-06 1999-02-03 Заместени пиридо- или пиримидосъдържащи 6,6- или 6,7- бициклични производни

Country Status (41)

Country Link
US (1) US6492520B1 (bg)
EP (1) EP0920429B1 (bg)
JP (1) JP3345021B2 (bg)
KR (1) KR20000029843A (bg)
CN (1) CN1093130C (bg)
AP (1) AP1096A (bg)
AR (1) AR008829A1 (bg)
AT (1) ATE232863T1 (bg)
AU (1) AU709203B2 (bg)
BG (1) BG103143A (bg)
BR (1) BR9710808A (bg)
CA (1) CA2262692C (bg)
CO (1) CO4900060A1 (bg)
CZ (1) CZ292806B6 (bg)
DE (1) DE69719193T2 (bg)
DK (1) DK0920429T3 (bg)
DZ (1) DZ2289A1 (bg)
EA (1) EA003188B1 (bg)
ES (1) ES2191183T3 (bg)
GT (1) GT199700089A (bg)
HK (1) HK1021734A1 (bg)
HR (1) HRP970432B1 (bg)
ID (1) ID17980A (bg)
IL (1) IL128188A0 (bg)
IS (1) IS4948A (bg)
MA (1) MA24296A1 (bg)
NO (1) NO313293B1 (bg)
NZ (1) NZ333727A (bg)
OA (1) OA10970A (bg)
PA (1) PA8435201A1 (bg)
PE (1) PE97098A1 (bg)
PL (1) PL331602A1 (bg)
SA (1) SA97180334A (bg)
SK (1) SK14099A3 (bg)
TN (1) TNSN97135A1 (bg)
TR (1) TR199900228T2 (bg)
TW (1) TW550265B (bg)
UY (1) UY24655A1 (bg)
WO (1) WO1998005661A1 (bg)
YU (1) YU5399A (bg)
ZA (1) ZA976954B (bg)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
AU755552B2 (en) 1998-11-12 2002-12-12 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
WO2000027850A2 (en) 1998-11-12 2000-05-18 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods relating thereto
US6432989B1 (en) * 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
IL139197A0 (en) * 1999-10-29 2001-11-25 Pfizer Prod Inc Use of corticotropin releasing factor antagonists and related compositions
CA2398956A1 (en) * 2000-02-14 2001-08-16 Japan Tobacco Inc. A pharmaceutical composition for prophylaxis or therapy of a postoperative stress
WO2001062718A1 (fr) * 2000-02-25 2001-08-30 Japan Tobacco, Inc. Dérivé de benzamide et utilisation de celui-ci
MY141144A (en) * 2000-03-02 2010-03-15 Smithkline Beecham Corp 1, 5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-dipyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
GB0011964D0 (en) 2000-05-18 2000-07-05 Suyal N Thick glass films with controlled refractive indices and their applications
IL155367A0 (en) 2000-10-23 2003-12-23 Smithkline Beecham Corp NOVEL 2,4,8-TRISUBSTITUTED-8h-PYRIDO[2,3,-d]PYRIMIDIN-7-ONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, PROCESSES FOR THE PREPARATION THEREOF, AND USE THEREOF IN THE PREPARATION OF MEDICAMENTS FOR TREATING CSBP/p38 KINASE MEDIATED DISEASES
GB0117396D0 (en) 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
JP2005504807A (ja) 2001-09-26 2005-02-17 バイエル・フアーマシユーチカルズ・コーポレーシヨン 抗糖尿病薬としての１，８−ナフチリジン誘導体
BR0309053A (pt) * 2002-04-19 2005-02-22 Smithkline Beecham Corp Compostos
FR2846657B1 (fr) * 2002-11-05 2004-12-24 Servier Lab Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1625121B1 (en) 2002-12-20 2010-02-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
WO2006074147A2 (en) 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
US7618975B2 (en) 2003-07-03 2009-11-17 Myriad Pharmaceuticals, Inc. 4-arylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof
US20050085479A1 (en) * 2003-08-27 2005-04-21 Pharmacia Corporation Mediated central nervous system compositions of a cyclooxygenase-2 selective inhibitor and a corticotropin releasing factor antagonist for the treatment of ischemic disorders or injury
US7897607B2 (en) * 2004-04-07 2011-03-01 Takeda Pharmaceutical Company Limited Cyclic compounds
WO2005111022A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidines derivatives for the treatment of abnormal cell growth
WO2005111016A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
MXPA06011658A (es) 2004-05-14 2006-12-14 Pfizer Prod Inc Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
JP2008535822A (ja) * 2005-03-25 2008-09-04 グラクソ グループ リミテッド 新規化合物
PE20100737A1 (es) * 2005-03-25 2010-11-27 Glaxo Group Ltd Nuevos compuestos
TW200724142A (en) 2005-03-25 2007-07-01 Glaxo Group Ltd Novel compounds
SG160438A1 (en) 2005-03-25 2010-04-29 Glaxo Group Ltd Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5- d]pyrimidin-2(1h)-one derivatives
US7973025B2 (en) 2005-05-26 2011-07-05 Neuron Systems, Inc. Compositions and methods of treating retinal disease
JP2009521480A (ja) 2005-12-21 2009-06-04 アボット・ラボラトリーズ 抗ウイルス化合物
ES2378473T3 (es) 2005-12-21 2012-04-12 Abbott Laboratories Compuestos antivirales
US7915411B2 (en) 2005-12-21 2011-03-29 Abbott Laboratories Anti-viral compounds
EP2345652A1 (en) 2005-12-21 2011-07-20 Abbott Laboratories Antiviral compounds
EP2094276A4 (en) 2006-12-20 2011-01-05 Abbott Lab ANTIVIRAL COMPOUNDS
CN102272134B (zh) 2008-12-09 2013-10-16 吉里德科学公司 Toll样受体调节剂
WO2010096426A2 (en) * 2009-02-20 2010-08-26 Emory University Compounds, compositions, methods of synthesis, and methods of treatment
SI2477987T1 (en) 2009-09-14 2018-03-30 Gilead Sciences, Inc. MODULATORS TO TOLL OF LIKE RECEPTORS
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
PL3176170T3 (pl) 2012-06-13 2019-05-31 Incyte Holdings Corp Podstawione związki tricykliczne jako inhibitory fgfr
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
CA2909207C (en) 2013-04-19 2021-11-02 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US10882868B2 (en) 2014-05-15 2021-01-05 Hoffmann-La Roche Inc. Compounds for treating spinal muscular atrophy
EP3663296B1 (en) * 2014-05-15 2023-05-17 F. Hoffmann-La Roche AG Process for the preparation of compounds useful for treating spinal muscular atrophy
US11116774B2 (en) 2014-07-11 2021-09-14 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of HIV
UY36298A (es) 2014-09-16 2016-04-29 Gilead Science Inc Formas sólidas de un modulador del receptor tipo toll
EP3848375B1 (en) 2014-09-16 2023-12-27 Gilead Sciences, Inc. Methods of preparing intermediates for toll-like receptor modulators
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EP3617205B1 (en) 2015-02-20 2021-08-04 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2017003724A1 (en) 2015-07-01 2017-01-05 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
BR112018003250A2 (pt) 2015-08-21 2018-09-25 Aldeyra Therapeutics Inc compostos deuterados e usos dos mesmos
SI3413892T1 (sl) 2016-02-12 2022-06-30 Cytokinetics, Incorporated Tetrahidroizokinolinski derivati
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
EP3658560A4 (en) 2017-07-25 2021-01-06 Crinetics Pharmaceuticals, Inc. SOMATOSTAT IN MODULATORS AND USES THEREOF
EP3694500A4 (en) 2017-10-10 2021-06-30 Aldeyra Therapeutics, Inc. TREATMENT OF INFLAMMATORY DISORDERS
CA3099287A1 (en) 2018-05-04 2019-11-07 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
WO2019213506A1 (en) 2018-05-04 2019-11-07 Incyte Corporation Salts of an fgfr inhibitor
WO2020033344A1 (en) 2018-08-06 2020-02-13 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
EP3856478A4 (en) 2018-09-25 2022-06-08 Aldeyra Therapeutics, Inc. FORMULATIONS FOR THE TREATMENT OF DRY EYE DISEASE
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
JP2022526917A (ja) 2019-03-26 2022-05-27 アルデイラ セラピューティクス， インコーポレイテッド 眼科用製剤およびその使用
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
KR20220100879A (ko) 2019-10-14 2022-07-18 인사이트 코포레이션 Fgfr 저해제로서의 이환식 헤테로사이클
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
MX2022006691A (es) 2019-12-04 2022-09-19 Incyte Corp Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605642A (en) 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
US5063245A (en) 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
EP0674641B1 (en) * 1992-12-17 1999-03-03 Pfizer Inc. Pyrrolopyrimidines as crf antagonists
TW370529B (en) * 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
TW574214B (en) * 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
JP2891544B2 (ja) * 1994-06-16 1999-05-17 ファイザー・インコーポレーテッド ピラゾロおよびピロロピリジン類
JP2898887B2 (ja) * 1994-08-31 1999-06-02 沖電気工業株式会社 Ｉｃカードの読み取り装置
EP0729758A3 (en) * 1995-03-02 1997-10-29 Pfizer Pyrazolopyrimidines and pyrrolopyrimidines to treat neuronal disorders and other diseases
JPH10506126A (ja) * 1995-05-12 1998-06-16 ニューロゲン コーポレイション 新規なデアザプリン誘導体；ｃｒｆ１特異性リガンドの新規なクラス
US6403599B1 (en) * 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
DK0778277T3 (da) * 1995-12-08 2003-10-27 Pfizer Substituerede heterocycliske derivater som CRF antagonister
KR100421626B1 (ko) 1996-02-07 2004-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 Crf수용체에대한길항제로서의피라졸로피리미딘
TW477787B (en) 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same

Also Published As

Publication number Publication date
CA2262692A1 (en) 1998-02-12
JP2000501116A (ja) 2000-02-02
UY24655A1 (es) 2000-09-29
AP1096A (en) 2002-08-26
CN1227552A (zh) 1999-09-01
NO990544L (no) 1999-03-31
AP9701052A0 (en) 1997-10-31
ZA976954B (en) 1999-02-05
TR199900228T2 (xx) 1999-03-22
NO313293B1 (no) 2002-09-09
EP0920429B1 (en) 2003-02-19
CZ292806B6 (cs) 2003-12-17
CA2262692C (en) 2002-06-11
MA24296A1 (fr) 1998-04-01
WO1998005661A1 (en) 1998-02-12
DE69719193T2 (de) 2003-09-25
CO4900060A1 (es) 2000-03-27
AR008829A1 (es) 2000-02-23
DE69719193D1 (de) 2003-03-27
ID17980A (id) 1998-02-12
KR20000029843A (ko) 2000-05-25
HRP970432B1 (en) 2002-10-31
TNSN97135A1 (fr) 2005-03-15
EP0920429A1 (en) 1999-06-09
GT199700089A (es) 1999-01-26
AU3356397A (en) 1998-02-25
TW550265B (en) 2003-09-01
ATE232863T1 (de) 2003-03-15
IS4948A (is) 1999-01-19
EA199900083A1 (ru) 1999-08-26
CZ41199A3 (cs) 2000-01-12
PL331602A1 (en) 1999-08-02
PA8435201A1 (es) 1999-12-27
US6492520B1 (en) 2002-12-10
EA003188B1 (ru) 2003-02-27
DK0920429T3 (da) 2003-05-12
DZ2289A1 (fr) 2002-12-25
HK1021734A1 (en) 2000-06-30
AU709203B2 (en) 1999-08-26
HRP970432A2 (en) 1998-08-31
JP3345021B2 (ja) 2002-11-18
OA10970A (en) 2001-11-05
SA97180334A (ar) 2005-12-03
NZ333727A (en) 2000-09-29
CN1093130C (zh) 2002-10-23
YU5399A (sh) 2002-03-18
NO990544D0 (no) 1999-02-05
IL128188A0 (en) 1999-11-30
ES2191183T3 (es) 2003-09-01
PE97098A1 (es) 1999-01-12
SK14099A3 (en) 2000-05-16
BR9710808A (pt) 1999-08-17

Similar Documents

Publication Publication Date Title
BG103143A (bg) Заместени пиридо- или пиримидосъдържащи 6,6- или 6,7- бициклични производни
BG103192A (bg) Заместени 6,6- хетеро- бициклени производни
MX9802383A (es) Derivados de pirimidina como antagonistas del receptor 5ht26.
GB2270075B (en) Substituted 2-phenyl-3-methoxypropenoate fungicides
MY131298A (en) 5-heteroyl indole derivatives
GR3030668T3 (en) Condensed indole derivatives as 5ht 4?-receptor antagonists.
WO1990003375A3 (en) Fluoro substituted benzocycloheptapyridine compounds, compositions and methods of use
HU9400623D0 (en) Substituted 1h-imidazo(4,5-c)quinolin-4-amines, pharmaceutical compositions containing them as active components and intermediates for them
TR199801679T2 (xx) Osteoporoz i�in birle�tirme terapisi.
CA2286076A1 (en) Use of 5ht3 antagonists for promoting intestinal lavage
FI990134A0 (fi) Pyridatsino-(4,5-beta)-kinoliini-5-oksidijohdannaisia, niiden valmistus ja niiden käyttö glysiiniantagonisteina
ES8507540A1 (es) Un procedimiento para preparar indeno-piridazinonas sustituidas.
AU1725188A (en) Pyridooxazinone-pyridone compounds, cardiotonic compositions including the same, and their uses
EP0267277A4 (en) COMPOSITIONS CONTAINING 1-SUBSTITUTED LACTAMS.
AU5686196A (en) Use of an "immunodeficiency-virus suppressing lymphokine (ISL)" to inhibit the replication of viruses, in particular of retroviruses
TR200001102T2 (tr) İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
AU2654692A (en) Pyrrolobenzoxazine derivatives as 5-ht agonists and antagonists
AU7345391A (en) Derivative of beta-phenylisoserine, preparation and utilisation thereof
GR3017885T3 (en) Substituted aminoacid amide derivatives, their preparation and use as fungicide.
BG102771A (bg) Нови диарилметилиденфуранови производни, метод за тяхното получаване и използването им като лекарствени средства
BG102213A (bg) Използване на дидепсипептиди като ендопаразитицидно средство, дидепсипептиди и метод за тяхното получаване
AU566900B2 (en) 2,3-dihydro-3-oxo-1h-isoindole derivatives
DE69019186D1 (de) N-substituierte-3-(Stickstoff-enthaltende 5-Ring)-Benzensulfonamid-Derivate, Verfahren zu ihrer Herstellung und Herbizid-Zusammensetzungen.
IE812399L (en) Benzodioxines
EP0562575A3 (en) N-substituted-3-(substited hydrazino)-benzenesulfonamide derivatives, prepation process thereof, and herbicidal compositions